$4.27
1.67% yesterday
Nasdaq, May 13, 10:00 pm CET
ISIN
US42328V5049
Symbol
HSDT

Helius Medical Technologies Inc Class A Stock price

$4.27
-0.23 5.02% 1M
-4.21 49.62% 6M
-5.78 57.53% YTD
-21.04 83.13% 1Y
-1,195.81 99.64% 3Y
-14,931.98 99.97% 5Y
-312,370.73 100.00% 10Y
Nasdaq, Closing price Tue, May 13 2025
+0.07 1.67%
ISIN
US42328V5049
Symbol
HSDT
Sector

Key metrics

Market capitalization $2.22m
Enterprise Value $1.11m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.58
P/S ratio (TTM) P/S ratio 5.16
P/B ratio (TTM) P/B ratio 1.34
Revenue growth (TTM) Revenue growth -35.03%
Revenue (TTM) Revenue $430.00k
EBIT (operating result TTM) EBIT $-14.46m
Free Cash Flow (TTM) Free Cash Flow $-11.58m
Cash position $1.11m
EPS (TTM) EPS $-47.81
P/E forward negative
P/S forward 4.35
EV/Sales forward 2.18
Short interest 0.02%
Show more

Is Helius Medical Technologies Inc Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,793 stocks worldwide.

Helius Medical Technologies Inc Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Helius Medical Technologies Inc Class A:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Helius Medical Technologies Inc Class A:

Buy
100%

Financial data from Helius Medical Technologies Inc Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
0.43 0.43
36% 36%
100%
- Direct Costs 0.61 0.61
9% 9%
142%
-0.17 -0.17
-
-40%
- Selling and Administrative Expenses 10 10
17% 17%
2,423%
- Research and Development Expense 3.82 3.82
35% 35%
888%
-14 -14
23% 23%
-3,351%
- Depreciation and Amortization 0.05 0.05
67% 67%
12%
EBIT (Operating Income) EBIT -14 -14
22% 22%
-3,362%
Net Profit -13 -13
47% 47%
-3,037%

In millions USD.

Don't miss a Thing! We will send you all news about Helius Medical Technologies Inc Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Helius Medical Technologies Inc Class A Stock News

Neutral
GlobeNewsWire
one day ago
United Healthcare approves claim for PoNS Device at out-of-network adjusted list price, becoming the second payer to join Anthem in providing PoNS reimbursement United Healthcare approves claim for PoNS Device at out-of-network adjusted list price, becoming the second payer to join Anthem in providing PoNS reimbursement
Neutral
GlobeNewsWire
13 days ago
NEWTOWN, Pa., April 30, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced today a 1-for-15 reverse split of its Class A common stock, par value $0.001 (“common stock”), effective at 5:00 pm Eastern time on May 1, 2025.
Neutral
GlobeNewsWire
2 months ago
--Revelation Neuro, Inc. is focused on advancing development of a Non-Implantable Artificial Intelligence (“AI”) Powered BCI Technology-- --Helius' existing IP portfolio and extensive data warehouse provides a solid foundation for AI algorithm development-- --Helius to Present at the 37 th Annual ROTH Conference on Monday, March 17 at 12:00pm PT-- NEWTOWN, Pa., March 13, 2025 (GLOBE NEWSWIRE) -...
More Helius Medical Technologies Inc Class A News

Company Profile

Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain's ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational Portable Neuromodulation Stimulator (PoNS), that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded in 2014 and is headquartered in Newtown, PA.

Head office United States
CEO Dane Andreeff
Employees 21
Founded 2014
Website www.heliusmedical.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today